Stock Events

Stock Events

Xeris Biopharma 

$8.80
72
+$0.11+1.27% Friday 20:00
+$0.00+0%Friday 23:52After hours

Statistics

Day High
8.81
Day Low
8.8
52W High
10.08
52W Low
4.87
Volume
35,779
Avg. Volume
-
Mkt Cap
1.52B
P/E Ratio
119.14
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-0.11
-0.07
-0.03
0.01
Expected EPS
0.012143
Actual EPS
N/A

Financials

0.19%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
291.85MRevenue
554,000Net Income

Analyst Ratings

10.00Average Price Target
The highest estimate is 10.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow XERS. It's not an investment recommendation.
NVIDIA
16
NVDA
Amazon
13
AMZN
Tesla
12
TSLA
Palantir Technologies
11
PLTR

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Mannkind
MNKD
Mkt Cap1.26B
MannKind Corporation focuses on the development and commercialization of inhaled therapeutic products for diabetes and orphan lung diseases, competing directly with Xeris's inhaled and injectable therapies.
Novo Nordisk
NVO
Mkt Cap218.94B
Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care, providing products that compete in the diabetes therapeutic area with Xeris.
Sanofi
SNY
Mkt Cap104.13B
Sanofi is a global life sciences company that offers a range of diabetes solutions, including insulin therapies that compete with Xeris's glucagon rescue pen.
Lilly(Eli) &
LLY
Mkt Cap1.06T
Eli Lilly and Company is a global healthcare leader that manufactures medicines for diabetes care, directly competing with Xeris's diabetes management products.
Astrazeneca
AZN
Mkt Cap266.15B
AstraZeneca operates in the biopharmaceutical sector, focusing on the development of new medicines for chronic diseases, including diabetes, thus competing with Xeris.
Merck
MRK
Mkt Cap305.12B
Merck & Co., Inc. offers innovative health solutions through its prescription medicines, vaccines, biologic therapies, and animal health products, including treatments for diabetes, making it a competitor.
Bristol-Myers Squibb
BMY
Mkt Cap117.58B
Bristol Myers Squibb is a global biopharmaceutical company whose portfolio of medicines includes treatments for diabetes and cardiovascular diseases, areas where Xeris also operates.
Pfizer
PFE
Mkt Cap137.76B
Pfizer Inc. is a research-based global biopharmaceutical company with a broad range of products in various therapeutic areas, including those competing with Xeris's offerings.
Tandem Diabetes Care
TNDM
Mkt Cap1.06B
Tandem Diabetes Care, Inc. designs, develops, and commercializes products for people with insulin-dependent diabetes, directly competing with Xeris's diabetes management solutions.
Insulet
PODD
Mkt Cap11.17B
Insulet Corporation is an innovative medical device company focused on making the lives of people with diabetes easier through its Omnipod Insulin Management System, competing in the diabetes care market with Xeris.

About

Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
Show more...
CEO
Mr. John P. Shannon
Employees
435
Country
United States
ISIN
US98422E1038

Listings

STU
DE
2B30.STU
MU
DE
69BN.MU
MU
DE
2B30.MU
LSE
GB
0A8E.LSE

0 Comments

Share your thoughts

FAQ

What is Xeris Biopharma stock price today?▼
The current price of XERS is $8.80 USD — it has increased by +1.27% in the past 24 hours. Watch Xeris Biopharma stock price performance more closely on the chart.
What is Xeris Biopharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Xeris Biopharma stocks are traded under the ticker XERS.
Is Xeris Biopharma stock price growing?▼
XERS stock has risen by +5.52% compared to the previous week, the month change is a +26.62% rise, over the last year Xeris Biopharma has showed a +72.21% increase.
What is Xeris Biopharma market cap?▼
Today Xeris Biopharma has the market capitalization of 1.52B
When is the next Xeris Biopharma earnings date?▼
Xeris Biopharma is going to release the next earnings report on August 06, 2026.
What were Xeris Biopharma earnings last quarter?▼
XERS earnings for the last quarter are 0.01 USD per share, whereas the estimation was -0 USD resulting in a +464.56% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Xeris Biopharma revenue for the last year?▼
Xeris Biopharma revenue for the last year amounts to 291.85M USD.
What is Xeris Biopharma net income for the last year?▼
XERS net income for the last year is 554,000 USD.
How many employees does Xeris Biopharma have?▼
As of July 18, 2026, the company has 435 employees.
In which sector is Xeris Biopharma located?▼
Xeris Biopharma operates in the Health & Wellness sector.
When did Xeris Biopharma complete a stock split?▼
Xeris Biopharma has not had any recent stock splits.
Where is Xeris Biopharma headquartered?▼
Xeris Biopharma is headquartered in Chicago, United States.